annual cash & cash equivalents:
$50.82M-$20.15M(-28.40%)Summary
- As of today (June 25, 2025), SPRY annual cash & cash equivalents is $50.82 million, with the most recent change of -$20.15 million (-28.40%) on December 31, 2024.
- During the last 3 years, SPRY annual cash & cash equivalents has fallen by -$9.25 million (-15.39%).
- SPRY annual cash & cash equivalents is now -75.86% below its all-time high of $210.52 million, reached on December 31, 2022.
Performance
SPRY Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$39.86M-$10.95M(-21.55%)Summary
- As of today (June 25, 2025), SPRY quarterly cash & cash equivalents is $39.86 million, with the most recent change of -$10.95 million (-21.55%) on March 31, 2025.
- Over the past year, SPRY quarterly cash & cash equivalents has dropped by -$16.14 million (-28.82%).
- SPRY quarterly cash & cash equivalents is now -81.06% below its all-time high of $210.52 million, reached on December 31, 2022.
Performance
SPRY quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
SPRY Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -28.4% | -28.8% |
| 3 y3 years | -15.4% | - |
| 5 y5 years | +107.2% | -33.6% |
SPRY Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -75.9% | at low | -81.1% | +8.8% |
| 5 y | 5-year | -75.9% | +107.2% | -81.1% | +8.8% |
| alltime | all time | -75.9% | +107.2% | -81.1% | +8.8% |
SPRY Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $39.86M(-21.6%) |
| Dec 2024 | $50.82M(-28.4%) | $50.82M(+28.1%) |
| Sep 2024 | - | $39.66M(+8.3%) |
| Jun 2024 | - | $36.63M(-34.6%) |
| Mar 2024 | - | $56.01M(-21.1%) |
| Dec 2023 | $70.97M | $70.97M(+17.2%) |
| Sep 2023 | - | $60.53M(-49.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2023 | - | $119.02M(+35.5%) |
| Mar 2023 | - | $87.86M(-58.3%) |
| Dec 2022 | $210.52M(+250.5%) | $210.52M(+372.1%) |
| Jun 2022 | - | $44.59M(-25.8%) |
| Dec 2021 | $60.06M(+144.9%) | - |
| Dec 2021 | - | $60.06M |
| Dec 2020 | $24.52M | - |
FAQ
- What is ARS Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for ARS Pharmaceuticals?
- What is ARS Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is ARS Pharmaceuticals quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for ARS Pharmaceuticals?
- What is ARS Pharmaceuticals quarterly cash & cash equivalents year-on-year change?
What is ARS Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of SPRY is $50.82M
What is the all time high annual cash & cash equivalents for ARS Pharmaceuticals?
ARS Pharmaceuticals all-time high annual cash & cash equivalents is $210.52M
What is ARS Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, SPRY annual cash & cash equivalents has changed by -$20.15M (-28.40%)
What is ARS Pharmaceuticals quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of SPRY is $39.86M
What is the all time high quarterly cash & cash equivalents for ARS Pharmaceuticals?
ARS Pharmaceuticals all-time high quarterly cash & cash equivalents is $210.52M
What is ARS Pharmaceuticals quarterly cash & cash equivalents year-on-year change?
Over the past year, SPRY quarterly cash & cash equivalents has changed by -$16.14M (-28.82%)